In ovarian cancer sera, 29.4% (10/34) was shown to have autoantibody to PARP1, 50.0% (17/34) was shown to have autoantibody to BRCA1, 5.9% (2/34) was shown to BRCA2, 29.4%(10/34) was shown to PARP1 and BRCA1, 0% (0/34) was shown to PARP1 and BRCA2, 2.9% (1/34) was shown to have autoantibody to BRCA1 and BRCA2, 0% (0/34) was shown to PARP1, BRCA1 and BRCA2. Here, BRCA2 is linked to ovarian carcinoma.